Last reviewed · How we verify
Anti-human Thymoglobulin
Anti-human thymoglobulin is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells in the circulation and lymphoid tissues.
Anti-human thymoglobulin is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells in the circulation and lymphoid tissues. Used for Prevention of acute organ rejection in renal transplantation, Treatment of acute rejection episodes in transplant recipients, Aplastic anemia.
At a glance
| Generic name | Anti-human Thymoglobulin |
|---|---|
| Also known as | (r-ATG ） |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | Polyclonal antithymocyte globulin (ATG) |
| Target | T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The drug is derived from immunized rabbit serum and contains polyclonal antibodies directed against human T-cell antigens. It binds to surface antigens on T lymphocytes, leading to their destruction through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This T-cell depletion suppresses the adaptive immune response and is used to prevent or treat rejection in transplantation and certain autoimmune conditions.
Approved indications
- Prevention of acute organ rejection in renal transplantation
- Treatment of acute rejection episodes in transplant recipients
- Aplastic anemia
Common side effects
- Fever
- Chills
- Leukopenia
- Thrombocytopenia
- Serum sickness
- Infusion reactions
- Infection (due to immunosuppression)
Key clinical trials
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (PHASE2)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis (NA)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (PHASE3)
- Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (PHASE1, PHASE2)
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome (PHASE2)
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: